Sanofi to pay Regeneron up to $8B to expand Dupixent partnership
by@Reuters
Summary
Sanofi has agreed to pay Regeneron up to $8 billion to expand their partnership on the Dupixent drug by adding new antibodies, with Regeneron taking the lead on research and development while Sanofi oversees global sales. This revised partnership structure allows both companies to equally share costs and profits from the new assets. The collaboration comes after they settled previous litigation regarding their ongoing work together and reflects the new CEO's commitment to proactively address key uncertainties in their pipeline, an observation noted by analysts from Jefferies.
Tokens
$SNY$REGN
Analysis
Sanofi: Sanofi is a major global pharmaceutical company focused on developing and commercializing treatments in areas including immunology and respiratory diseases. It maintains a long-standing collaboration with Regeneron on the Dupixent antibody therapy. In this news, Sanofi is expanding that partnership by committing resources to additional early-stage antibodies while leading global sales efforts. Regeneron: Regeneron is a biotechnology company specializing in the discovery and development of antibody-based medicines, often in partnership with larger firms. It leads research and development in its established Dupixent collaboration with Sanofi. Under the reported expansion, Regeneron gains responsibility for new antibody assets and retains an option to join Sanofi's lunsekimig program after COPD trials conclude. Hugo Lhomedet: Hugo Lhomedet is a Reuters journalist based in Gdansk who covers pharmaceutical industry deals and developments. He co-authored the reporting on the Sanofi-Regeneron antibody partnership expansion announced in this news item. His coverage highlights settlement of prior litigation and structural terms of the updated collaboration. Matthieu Huchet: Matthieu Huchet is a Reuters journalist based in Gdansk focused on corporate and biotech news. He co-authored the article detailing Sanofi's expanded Dupixent-related agreement with Regeneron. His reporting includes analyst perspectives on the strategic implications of the deal. Prior Resolution: The companies have settled earlier litigation related to their ongoing collaboration. Strategic Outlook: The move signals the new CEO's focus on addressing key uncertainties in the pipeline through proactive collaboration adjustments. Partnership Structure: Under the expanded agreement, Regeneron leads research and development while Sanofi leads global sales, with costs and profits split equally for new assets.
Categories
macro